NBIX Maintained by Citigroup -- Price Target Raised to $253

gurufocus.com · 2026-09-03

Analyst Rating Update for Neurocrine Biosciences (NBIX)On September 3, 2026, Citigroup maintained a 'Buy' rating on Neurocrine Biosciences (NBIX) and raised the

Read the full story at gurufocus.com →